CompletedPhase 4

Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke

France128 participantsStarted 2003-06

Plain-language summary

The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * clinically defined lacunar syndrome 3 months before inclusion * small deep infarct on diffusion MRI (Diffusion Weighted Imaging) * no atherothrombotic, cardio-embolic, or other rarer cause. Exclusion Criteria: * patients with past coronary event * contra-indication for assessment of vasomotor reactivity * patients being on statin therapy at the time of brain infarction * contra-indication for statin therapy * patient still under statin therapy

What they're measuring

Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients. CVR, humeral and carotid vasoreactivity will be measured in all patients at M0 and M3.

Trial details

NCT IDNCT00163150

SponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Cerebrovascular Accident trials